{"classes":[{"categories":[{"measurements":[{"comment":"The confidence intervals are generated via the Brookmeyer-Crowley method (if a limit of the interval does not intersect the median, then it is recorded as not able to be estimated with a dash.","groupId":"OG000","lowerLimit":"4.3","upperLimit":"NA","value":"8.4"},{"comment":"The confidence intervals are generated via the Brookmeyer-Crowley method (if a limit of the interval does not intersect the median, then it is recorded as not able to be estimated with a dash.","groupId":"OG001","lowerLimit":"2.0","upperLimit":"NA","value":"3.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the duration of time from the date of study enrollment until time of disease relapse, disease progression, death, or 10 years post-treatment, whichever occurs first. The progression-free survival (PFS) after VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide) in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) will be estimated using progression or death without progression as events, using a Kaplan-Meier curve. The median will be determined and presented with its associated 95% confidence interval. Progression was measured by the Lugano criteria and is appearance of any new nodal lesion ≥1.6 cm in greatest tumor dimension or ≥1.1 cm in short axis during or after the end of therapy, even if other lesions are decreasing in size.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cohort 1, Arm 1: Participants with primary diffuse large B-cell lymphoma of the central nervous system (CNS) primary central nervous system lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL).\n\nExperimental - Nivolumab on Day 1 with lenalidomide (days 1-14) for a 21-day cycle. Following Window, VIPOR-Nivo (venetoclax, ibrutinib, prednisone, Obinutuzumab, lenalidomide, and nivolumab) in 21-day cycles for up to 6 cycles.","id":"OG000","title":"Lenalidomide+Nivolumab Followed by Venetoclax, Ibrutinib,Prednisone, Obinutuzumab, Lenalidomide-Nivo"},{"description":"Participants with primary diffuse large B-cell lymphoma of the central nervous system (CNS) primary central nervous system lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL). VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide) in 21-day cycles for up to 6 cycles.","id":"OG001","title":"Cohort 1, Arm 2: Experimental- VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2.6 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}